Back to Authors

Andraos, T.Y.

0000-0001-5554-4820

Mayo Clinic

The Ohio State University Wexner Medical Center

Citations 1

Scalp Irradiation with 3D-Milled Bolus: Initial Dosimetric and Clinical Experience
Dibs, Khaled , Gogineni, Emile , Jhawar, Sachin R. , Baliga, Sujith , Grecula, J.C., Mitchell, Darrion , Palmer, Joshua D. , Haglund, Karl, Andraos, T.Y. , Zoller, Wesley , Ewing, Ashlee, Bonomi, Marcelo , Bhateja, Priyanka, Tinoco, Gabriel , Rocco, James W. , Old, Matthew , Gamez, Mauricio E. , Chakravarti, Arnab , Konieczkowski, David J. , Blakaj, Dukagjin , Jhawar, Sachin R , Mitchell, Darrion L , Palmer, Joshua D , Bhateja, Priyanka , Bonomi, Marcelo , Tinoco, Gabriel , Chakravarti, Arnab , Liebner, David A.

Cancers | February 6, 2024 | Volume: 16 | Issue: 4 | Pages: 688

10.3390/cancers16040688 Get It

Background and purpose: A bolus is required when treating scalp lesions with photon radiation therapy. Traditional bolus materials face several issues, including air gaps and setup difficulty due to irregular, convex scalp geometry. A 3D-milled bolus is custom-formed to match individual patient anatomy, allowing improved dose coverage and homogeneity. Here, we describe the creation process of a 3D-milled bolus and report the outcomes for patients with scalp malignancies treated with Volumetric Modulated Arc Therapy (VMAT) utilizing a 3D-milled bolus. Materials and methods: Twenty-two patients treated from 2016 to 2022 using a 3D-milled bolus and VMAT were included. Histologies included squamous cell carcinoma (n = 14, 64%) and angiosarcoma (n = 8, 36%). A total of 7 (32%) patients were treated in the intact and 15 (68%) in the postoperative setting. The median prescription dose was 66.0 Gy (range: 60.0–69.96). Results: The target included the entire scalp for 8 (36%) patients; in the remaining 14 (64%), the median ratio of planning target volume to scalp volume was 35% (range: 25–90%). The median dose homogeneity index was 1.07 (range: 1.03–1.15). Six (27%) patients experienced acute grade 3 dermatitis and one (5%) patient experienced late grade 3 skin ulceration. With a median follow-up of 21.4 months (range: 4.0–75.4), the 18-month rates of locoregional control and overall survival were 75% and 79%, respectively. Conclusions: To our knowledge, this is the first study to report the clinical outcomes for patients with scalp malignancies treated with the combination of VMAT and a 3D-milled bolus. This technique resulted in favorable clinical outcomes and an acceptable toxicity profile in comparison with historic controls and warrants further investigation in a larger prospective study.